Elena Marcello

List of Publications by Year
in descending order

63 papers	3,412 citations	159358 30 h-index	149479 56 g-index
69 all docs	69 docs citations	69 times ranked	4737 citing authors

#	Article	IF	Citations
1	Sex-Specific Features of Microglia from Adult Mice. Cell Reports, 2018, 23, 3501-3511.	2.9	417
2	Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Brain, 2008, 131, 3380-3394.	3.7	223
3	Î±-Secretase ADAM10 as Well as Î±APPs Is Reduced in Platelets and CSF of Alzheimer Disease Patients. Molecular Medicine, 2002, 8, 67-74.	1.9	215
4	Synapse-Associated Protein-97 Mediates Â-Secretase ADAM10 Trafficking and Promotes Its Activity. Journal of Neuroscience, 2007, 27, 1682-1691.	1.7	164
5	Platelet APP, ADAM 10 and BACE alterations in the early stages of Alzheimer disease. Neurology, 2004, 62, 498-501.	1.5	159
6	Acetylcholinesterase inhibitors increase ADAM10 activity by promoting its trafficking in neuroblastoma cell lines. Journal of Neurochemistry, 2004, 90, 1489-1499.	2.1	129
7	Synaptic Localization and Activity of ADAM10 Regulate Excitatory Synapses through N-Cadherin Cleavage. Journal of Neuroscience, 2010, 30, 16343-16355.	1.7	102
8	Endocytosis of synaptic ADAM10 in neuronal plasticity and Alzheimerâ€™s disease. Journal of Clinical Investigation, 2013, 123, 2523-2538.	3.9	96
9	Synaptic Dysfunction in Alzheimerâ€™s Disease. Advances in Experimental Medicine and Biology, 2012, 970, 573-601.	0.8	94
10	[alpha]-Secretase ADAM10 as well as [alpha]APPs is reduced in platelets and CSF of Alzheimer disease patients. Molecular Medicine, 2002, 8, 67-74.	1.9	88
11	Blood cell markers in Alzheimer Disease: Amyloid Precursor Protein form ratio in platelets. Experimental Gerontology, 2010, 45, 53-56.	1.2	76
12	AÎ² leads to Ca2+ signaling alterations and transcriptional changes in glial cells. Neurobiology of Aging, 2013, 34, 511-522.	1.5	76
13	Blocking ADAM10 synaptic trafficking generates a model of sporadic Alzheimerâ€™s disease. Brain, 2010, 133, 3323-3335.	3.7	71
14	Dual role of CaMKII-dependent SAP97 phosphorylation in mediating trafficking and insertion of NMDA receptor subunit NR2A. Journal of Neurochemistry, 2007, 100, 1032-1046.	2.1	67
15	Dendritic Spines in Alzheimerâ€™s Disease: How the Actin Cytoskeleton Contributes to Synaptic Failure. International Journal of Molecular Sciences, 2020, 21, 908.	1.8	65
16	Postsynaptic densityâ€“membrane associated guanylate kinase proteins (PSDâ€“MAGUKs) and their role in CNS disorders. Neuroscience, 2009, 158, 324-333.	1.1	64
17	microRNA 221 Targets ADAM10 mRNA and is Downregulated in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 61, 113-123.	1.2	64
18	Rabphilin 3A retains NMDA receptors at synaptic sites through interaction with GluN2A/PSD-95 complex. Nature Communications, 2015, 6, 10181.	5.8	59

#	Article	IF	Citations
19	SAP97-mediated ADAM10 trafficking from Golgi outposts depends on PKC phosphorylation. Cell Death and Disease, 2014, 5, e1547-e1547.	2.7	56
20	An Arginine Stretch Limits ADAM10 Exit from the Endoplasmic Reticulum. Journal of Biological Chemistry, 2010, 285, 10376-10384.	1.6	53
21	Amyloid flirting with synaptic failure: Towards a comprehensive view of Alzheimer's disease pathogenesis. European Journal of Pharmacology, 2008, 585, 109-118.	1.7	52
22	ADAM10 in Alzheimer's disease: Pharmacological modulation by natural compounds and its role as a peripheral marker. Biomedicine and Pharmacotherapy, 2019, 113, 108661.	2.5	52
23	A light-gated potassium channel for sustained neuronal inhibition. Nature Methods, 2018, 15, 969-976.	9.0	47
24	SAP97-mediated local trafficking is altered in Alzheimer disease patients' hippocampus. Neurobiology of Aging, 2012, 33, 422.e1-422.e10.	1.5	46
25	Searching for new animal models of Alzheimerâ€²s disease. European Journal of Pharmacology, 2010, 626, 57-63.	1.7	44
26	ADAM10 as a therapeutic target for brain diseases: from developmental disorders to Alzheimerâ€™s disease. Expert Opinion on Therapeutic Targets, 2017, 21, 1017-1026.	1.5	43
27	SAP97 Directs the Localization of Kv4.2 to Spines in Hippocampal Neurons. Journal of Biological Chemistry, 2007, 282, 28691-28699.	1.6	40
28	Modeling Alzheimerâ€™s disease: from past to future. Frontiers in Pharmacology, 2013, 4, 77.	1.6	40
29	Ring finger protein 10 is a novel synaptonuclear messenger encoding activation of NMDA receptors in hippocampus. ELife, 2016, 5, e12430.	2.8	39
30	Intermittent thetaâ€burst stimulation rescues dopamineâ€dependent corticostriatal synaptic plasticity and motor behavior in experimental parkinsonism: Possible role of glial activity. Movement Disorders, 2017, 32, 1035-1046.	2.2	38
31	Synapse-to-nucleus communication: from developmental disorders to Alzheimer's disease. Current Opinion in Neurobiology, 2018, 48, 160-166.	2.0	34
32	Anti-GluA3 antibodies in frontotemporal dementia: effects on glutamatergic neurotransmission and synaptic failure. Neurobiology of Aging, 2020, 86, 143-155.	1.5	34
33	Linking NMDA Receptor Synaptic Retention to Synaptic Plasticity and Cognition. IScience, 2019, 19, 927-939.	1.9	31
34	Artificial neural networks allow the use of simultaneous measurements of Alzheimer disease markers for early detection of the disease. Journal of Translational Medicine, 2005, 3, 30.	1.8	30
35	The neuropeptide <u>PACAP38</u> induces dendritic spine remodeling through ADAM10/N-Cadherin signaling pathway. Journal of Cell Science, 2012, 125, 1401-6.	1.2	29
36	Alzheimer's disease and modern lifestyle: what is the role of stress?. Journal of Neurochemistry, 2015, 134, 795-798.	2.1	29

#	Article	IF	Citations
37	Synaptic dysfunction in Alzheimer's disease: From the role of amyloid Î²-peptide to the Î±-secretase ADAM10. European Journal of Pharmacology, 2017, 817, 30-37.	1.7	29
38	Biological, Neuroimaging, and Neurophysiological Markers in Frontotemporal Dementia: Three Faces of the Same Coin. Journal of Alzheimer's Disease, 2018, 62, 1113-1123.	1.2	29
39	Cyclase-associated protein 2 dimerization regulates cofilin in synaptic plasticity and Alzheimer's disease. Brain Communications, 2020, 2, fcaa086.	1.5	29
40	Fingolimod Limits Acute AÎ² Neurotoxicity and Promotes Synaptic Versus Extrasynaptic NMDA Receptor Functionality in Hippocampal Neurons. Scientific Reports, 2017, 7, 41734.	1.6	27
41	Synaptic dysfunction in early phases of Alzheimer's Disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2022, 184, 417-438.	1.0	27
42	ADAM10 gene expression in the blood cells of Alzheimer's disease patients and mild cognitive impairment subjects. Biomarkers, 2015, 20, 196-201.	0.9	25
43	Loss of Ryanodine Receptor 2 impairs neuronal activity-dependent remodeling of dendritic spines and triggers compensatory neuronal hyperexcitability. Cell Death and Differentiation, 2020, 27, 3354-3373.	5.0	25
44	Modulatory effect of acetyl-l-carnitine on amyloid precursor protein metabolism in hippocampal neurons. European Journal of Pharmacology, 2008, 597, 51-56.	1.7	24
45	Trafficking in neurons: Searching for new targets for Alzheimer's disease future therapies. European Journal of Pharmacology, 2013, 719, 84-106.	1.7	24
46	ADAM10 in Synaptic Physiology and Pathology. Neurodegenerative Diseases, 2014, 13, 72-74.	0.8	24
47	Predicting Cognitive Decline in Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2004, 18, 32-34.	0.6	23
48	CAPtâ€™n of Actin Dynamics: Recent Advances in the Molecular, Developmental and Physiological Functions of Cyclase-Associated Protein (CAP). Frontiers in Cell and Developmental Biology, 2020, 8, 586631.	1.8	23
49	Proximity ligation assay reveals both pre- and postsynaptic localization of the APP-processing enzymes ADAM10 and BACE1 in rat and human adult brain. BMC Neuroscience, 2020, 21, 6.	0.8	18
50	ADAM10 Plasma and CSF Levels Are Increased in Mild Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2021, 22, 2416.	1.8	17
51	The development of ADAM10 endocytosis inhibitors for the treatment of Alzheimerâ€™s disease. Molecular Therapy, 2022, 30, 2474-2490.	3.7	15
52	The Synaptonuclear Messenger RNF10 Acts as an Architect of Neuronal Morphology. Molecular Neurobiology, 2019, 56, 7583-7593.	1.9	12
53	Transcranial Magnetic Stimulation Exerts â€œRejuvenationâ€•Effects on Corticostriatal Synapses after Partial Dopamine Depletion. Movement Disorders, 2021, 36, 2254-2263.	2.2	10
54	Analysis of mRNA and Protein Levels of CAP2, DLG1 and ADAM10 Genes in Post-Mortem Brain of Schizophrenia, Parkinsonâ€™s and Alzheimerâ€™s Disease Patients. International Journal of Molecular Sciences, 2022, 23, 1539.	1.8	10

#	Article	IF	Citations
55	Disease association of cyclase-associated protein (CAP): Lessons from gene-targeted mice and human genetic studies. European Journal of Cell Biology, 2022, 101, 151207.	1.6	10
56	The epilepsy-associated protein PCDH19 undergoes NMDA receptor-dependent proteolytic cleavage and regulates the expression of immediate-early genes. Cell Reports, 2022, 39, 110857.	2.9	10
57	Amyloid-Î² Oligomers Regulate ADAM10 Synaptic Localization Through Aberrant Plasticity Phenomena. Molecular Neurobiology, 2019, 56, 7136-7143.	1.9	9
58	Lack of the Actin Capping Protein, Eps8, Affects NMDA-Type Glutamate Receptor Function and Composition. Frontiers in Molecular Neuroscience, 2018, 11, 313.	1.4	7
59	ATM rules neurodevelopment and glutamatergic transmission in the hippocampus but not in the cortex. Cell Death and Disease, 2022, 13, .	2.7	5
60	Looking at Alzheimerâ€™s Disease Pathogenesis from the Nuclear Side. Biomolecules, 2021, 11, 1261.	1.8	3
61	Cyclase-associated protein 2 (CAP2) controls MRTF-A localization and SRF activity in mouse embryonic fibroblasts. Scientific Reports, 2021, 11, 4789.	1.6	2
62	P3-036: SAP97 DRIVES ADAM10 FROM GOLGI OUTPOSTS TO THE SYNAPSE THROUGH A PKC-DEPENDENT PHOSPHORYLATION PROCESS. , 2014, 10, P640-P641.		0
63	O2-06-02: DEVELOPMENT OF INNOVATIVE TOOLS FOR ALZHEIMER'S DISEASE THERAPY. , 2014, 10, P174-P175.		0